- Help Us Help You By Completing The IMF Thalidomide Insurance Survey
The IMF has been discussing thalidomide insurance reimbursement issues and potential solutions with the FDA and Celgene. To take the next step, we need to gather data from patients who have taken thalidomide and/or who were recommended thalidomide but subsequently did not take the drug. Help us help you by completing this short web-based survey at survey.myeloma.org. All individual responses will be kept strictly confidential.
- Amyloidosis: the elusive killer
It's uncommon, and many doctors go through their careers without diagnosing it. But it may not be as uncommon as some think, experts agree, for that very reason. (from the Salt Lake City Deseret News)
- Cancer Statistics, 2003
In spite of the continued decline in cancer death rates in the most recent time period, the total number of recorded cancer deaths in the United States continues to increase slightly due to the aging and expanding population. (from the American Cancer Society's journal CANCER)
- Curing patient's cancer may not be best idea
For years, doctors and patients have accepted that certain health problems, such as diabetes or heart disease, are chronic illnesses that can't be cured. Why should cancer be any different? (from the Canton, Ohio Repository)
What's New in Myeloma Research:
- Antiangiogenic therapy may be of use in hematological cancer
Study demonstrates increased expression and production levels of VEGF in myeloma compared to non-myelomatous hematological lines, resistance to hypoxia and enhancement of VEGF-A production by hypoxia in myeloma, and direct growth inhibition of myeloma cells due to apoptosis and G(1) arrest caused by TNF-alpha upregulation induced by thalidomide.
- Prognostic value of angiogenesis in solitary bone plasmacytoma
Shaji Kumar, Rafael Fonseca, Angela Dispenzieri, Martha Q. Lacy, John A. Lust, Linda Wellik, Thomas E. Witzig, Morie A. Gertz, Robert A. Kyle, Philip R. Greipp, and S. Vincent Rajkumar
Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma.
- Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors
Fabrice Bovia, Patrick Salmon, Thomas Matthes, Krisztian Kvell, Tuan H. Nguyen, Christiane Werner-Favre, Marc Barnet, Monika Nagy, Florence Leuba, Jean-Francois Arrighi, Vincent Piguet, Didier Trono, and Rudolf H. Zubler
HIV vectors are promising tools for studies of gene functions in primary human B cells and myeloma cells for the purposes of research.
- Clinical and Biologic Implications of Recurrent Genomic Aberrations in Myeloma
Rafael Fonseca*, Emily Blood, Montserrat Rue, David Harrington, Martin M Oken, Robert A Kyle, Gordon W Dewald, Brian Van Ness, Scott A Van Wier, Kimberly J Henderson, Richard J Bailey, and Philip R Greipp
This molecular cytogenetic classification identifies patients into poor, intermediate and good risk categories.
- A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
Jean-Jacques Body, M.D., Ph.D., Philip Greipp, M.D., Robert E. Coleman, M.D., Thierry Facon, M.D., Filip Geurs, M.D., Jean-Paul Fermand, M.D., Jean-Luc Harousseau, M.D., Allan Lipton, M.D., Xavier Mariette, M.D., Catherine D. Williams, M.D., Arline Nakanishi, M.S., Donna Holloway, Ph.D., Steven W. Martin, Ph.D., Colin R. Dunstan, Ph.D., Pirow J. Bekker, M.D., Ph.D.
AMGN-0007 is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.
What's New in Clinical Trials:
We have changed the format of this section to better reflect the mission of the Myeloma Minute, namely to bring you the latest information on pertinent topics. So look to What's New in Clinical Trials in the Minute to bring you news about the opening and closing of trials.
- Results of Mayo Study of R115777 to be published in next issue of Blood
Jorge Cortes, Maher Albitar, Deborah Thomas, Francis Giles, Razelle Kurzrock, Alain Thibault, Wayne Rackoff, Charles Koller, Susan O'Brien, Guillermo Garcia-Manero, Moshe Talpaz, and Hagop Kantarjian
If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find CenterWatch and EmergingMed. The IMF has entered into partnerships with them to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing material from the National Cancer Institute.
Quality of Life Update:
- Travel and Cancer
CancerBACUP, a UK site for cancer information, discusses issues—many of them applicable to Americans—that may arise for people who have received a diagnosis of cancer and are contemplating foreign travel.
If you are interested in joining a support group, use the IMF's worldwide support group directory to find one that meets near you. You can also join our online support group.
If you have a topic of particular interest that you would like us to feature, if you are starting a support group, or if you are in a support group that is doing something to make a real difference in the lives of mutiple myeloma patients and their families and friends, let us know.
Upcoming Seminars and Conferences:
- One Voice Against Cancer (OVAC) Training and Lobby Days
April 7-8, 2003
The 4th Annual One Voice Against Cancer Lobby Days will be held at the the Crowne Plaza Hotel in Washington, DC. The Crowne Plaza is located at the corner of 14th and K Streets. The IMF will secure a block of rooms for advocates who want to attend.
Details including website registration will be posted in next week's Myeloma Minute. The registration fee will be $30. However, for those registering after March 15, registration will be increased to $100.
This year's lobby day coincides with Washington, DC's Cherry Blossom festivities.
If you are interested in attending or want more information, please contact Greg Brozeit at email@example.com.
- IXth Annual International Workshop On Multiple Myeloma
May 23-27, 2003
Every two years, the myeloma scientific community gathers from around the world to discuss the state of the art in myeloma treatment and research. This year they are meeting in the ancient and beautiful city of Salamanca.
- "Hair Cares"
June 22, 2003
Curries Hair, Skin & Nail Salon, Glen Mills, PA
- Make it Valentine's Day every day courtesy of IMFers Esther and Herman Adler, of Adler & Company Jewelers in Los Angeles. Buy beautiful jewelry at wholesale prices and—if you tell them you are an IMFer—a portion of the proceeds will be donated to the IMF. They make it so easy, too. They can work from digital pictures if you cannot meet with them, and they have a return policy if you are not completely satisfied. Call them at 213-624-1945 for more information.
Items of Interest:
- Myeloma Matrix
The Myeloma Matrix provides updated information about drugs beginning with pre-clinical developments and tracks drugs as they proceed through Phases I – III of clinical trials, drugs that have been FDA approved, and information on trials that are being conducted by NCI- sponsored cooperative groups as well as other myeloma study groups. The online version is updated regularly. If you would like to have a printed copy, call the toll-free hotline (800) 452-2873.
- NexCura Cancer Profiler
The Cancer Profiler is a free service (no hidden fees or charges). Its tools provide you with information specific to your cancer diagnosis to help you make more informed treatment decisions along with your physician.
- Expert Opinions on Multiple Myeloma
A multimedia, CME-accredited program for physicians with the chance to see world-renowned myeloma specialists sharing their knowledge, discussing treatment choices, and comparing their perspectives on controversial issues in multiple myeloma and related diseases.
An exciting new way for myeloma patients to get involved at patient seminars.
- Bank On A Cure™
The IMF is pleased to announce the launch of Bank On A Cure™, a groundbreaking international collaborative effort to establish a method to find new treatments while customizing care for current patients.
- Myeloma At The Movies
It has been our goal to bring our Patient & Family Seminars to people around the country who might not be able to attend an actual meeting, so we have set up a video lending library....
Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Please consider showing your support by making a tax-deductible donation today. Donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.
Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here.